Sign inJoin waitlistJoin the waitlist

Marlise Luskin

Associate Program Director, Dana-Farber/Mass General Brigham Hematology/Oncology Fellowship Program · Mass General Brigham

Credentials: · · · · · ·

History

Dana-Farber/Mass General Brigham Hematology/Oncology Fellowship
Present
Mass General Brigham
Present

Hematology and Medical Oncology
University of Pennsylvania
2012–2015
Internal Medicine
Brigham and Women's Hospital
2009–2012
The Raymond and Ruth Perelman School of Medicine at the University of Pennsylvania
2005–2009

Research

Prediction of risk for myeloid malignancy in clonal hematopoiesis
NEJM Evidence · 2023 · 288 citations
Increasing use of allogeneic hematopoietic cell transplantation in patients aged 70 years and older in the United States
Blood · 2017 · 256 citations
Parental acceptance of the human papillomavirus vaccine
Journal of Adolescent Health · 2005 · 181 citations

Daniel DeAngelo
57 papers
Richard Stone
42 papers
Jacqueline Garcia
32 papers
Shai Shimony
29 papers
Eric Winer
27 papers
Evan Chen
22 papers · 5 as a fellow
Martha Wadleigh
22 papers
Coleman Lindsley
19 papers
Maximilian Stahl
16 papers
Andrew Brunner
15 papers
Andrew Lane
14 papers
Wendy Stock
12 papers

Clinical trials

ALL Backbone in AYAs
Principal investigator · Recruiting · Phase 2
Dana-Farber Cancer Institute
2026–2035
Venetoclax Plus Inotuzumab for B-ALL
Principal investigator · Active not recruiting · Phase 1
Dana-Farber Cancer Institute
2021–2026
ABL001 + Dasatinib + Prednisone + Blinatumomab in BCR-ABL+ B-ALL or CML
Principal investigator · Recruiting · Phase 1
Marlise Luskin, MD
2018–2027
Venetoclax and Chemotherapy as Frontline Therapy in Older Patients and Patients With Relapsed/Refractory ALL
Principal investigator · Active not recruiting · Phase 1, Phase 2
Dana-Farber Cancer Institute
2017–2028